SAB Biotherapeutics (SAB Biotherapeutics) Cash Flow from Financing : $66.77 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is SAB Biotherapeutics Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, SAB Biotherapeutics paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.48 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $67.16 Mil on other financial activities. In all, SAB Biotherapeutics earned $67.64 Mil on financial activities for the three months ended in Dec. 2023.

SAB Biotherapeutics Cash Flow from Financing Historical Data

The historical data trend for SAB Biotherapeutics's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SAB Biotherapeutics Cash Flow from Financing Chart

SAB Biotherapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow from Financing

3.68

8.98

35.89

1.05

66.77

SAB Biotherapeutics Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash Flow from Financing	Get a 7-Day Free Trial										8.39	-0.36	-0.36	-0.14	67.64

SAB Biotherapeutics Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

SAB Biotherapeutics's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

	Cash Flow from Financing		(A: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	-0.39	+	7.5	+	0	+	59.663
=	66.77

SAB Biotherapeutics's Cash from Financing for the quarter that ended in Dec. 2023 is:

	Cash Flow from Financing		(Q: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	0.478	+	0	+	0	+	67.159
=	67.64

Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $66.77 Mil.

SAB Biotherapeutics (NAS:SABS) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

SAB Biotherapeutics's issuance of stock for the three months ended in Dec. 2023 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

SAB Biotherapeutics's repurchase of stock for the three months ended in Dec. 2023 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

SAB Biotherapeutics's net issuance of debt for the three months ended in Dec. 2023 was $0.48 Mil. SAB Biotherapeutics received $0.48 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

SAB Biotherapeutics's net issuance of preferred for the three months ended in Dec. 2023 was $0.00 Mil. SAB Biotherapeutics paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

SAB Biotherapeutics's cash flow for dividends for the three months ended in Dec. 2023 was $0.00 Mil. SAB Biotherapeutics received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

SAB Biotherapeutics's other financing for the three months ended in Dec. 2023 was $67.16 Mil. SAB Biotherapeutics received $67.16 Mil on other financial activities.

SAB Biotherapeutics Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of SAB Biotherapeutics's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

SAB Biotherapeutics (SAB Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SAB Biotherapeutics Inc (NAS:SABS) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

N/A

Address

2100 East 54th Street North, Sioux Falls, SD, USA, 57104

Website

https://www.sabbiotherapeutics.com

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Executives

Eddie Joe Sullivan	director, 10 percent owner, officer: Chief Executive Officer	2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104
Michael King	officer: CHIEF FINANCIAL OFFICER	2100 EAST 54TH STREET NORTH, SIOUX FALLS SD 57104
Samuel J Reich	director, officer: Executive Chairman	ACUITY PHARMACEUTICALS INC, 3701 MARKET STREET, PHILADELPHIA PA 19104
Sessa Capital Im, L.p.	director	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Andrew Moin	director	2100 EAST 54TH STREET NORTH, SIOUX FALLS SD 57104
Sessa Capital (master), L.p.	director	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Im Gp, Llc	director	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
John Petry	director	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Gp, Llc	director	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Erick Lucera	director	138 THISTLE ROAD, NORTH ANDOVER MA 08145
David Charles Link	director	2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104
Christine E Hamilton	director, 10 percent owner	225 S MAIN AVE, P O BOX 5000, SIOUX FALLS SD 57117
Scott Giberson	director	2100 EAST 54TH STREET NORTH, SIOUX FALLS SD 57104
Alexandra Kropotova	officer: Chief Medical Officer	RIVER OAKS TOWER, 8800 HSC PARKWAY, BYRAN TX 77807
Jeffrey G Spragens	director	4400 BISCAYNE BOULEVARD, SUITE 1500, MIAMI FL 33137